Hugel (145020 KS): South Korea’s Low-Cost Botox Leader Now Expanding to the US
On Tuesday, Meera Kapoor wrote about how GLP-1 drugs cause people's skin to become saggy – the effect that's now popularly known as "Ozempic...
103 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
​Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
872 Views
Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q23
Hugel has received FDA approval for its botulinum toxin Letybo and becomes the only Korean company and one of the top 3 players globally that have...
869 Views
Hugel (145020) Vs Medy Tox: Market Neutral Trade
​Hugel Inc is undervalued with strong growth potential, while Medy Tox is neglecting core strategy for R&D. Long Hugel and Short Medy Tox strategy...
124 Views
Hugel Inc (145020 KS): Record High 1Q Earnings; Global Expansion to Accelerate Growth Ahead
​Hugel reported strong 1Q26 results, with 22% operating profit growth on 30% revenue growth. The company aims for 2028 revenue of KRW900B while...
124 Views